Key Takeaways:
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) received marketing authorization from the European Commission for its drug PYRUKYND, or mitapivat, to treat anemia in adults with all forms of thalassemia, making it the first therapy for this broad patient group in the EU.
“Securing approvals across four key markets – the U.S., Saudi Arabia, United Arab Emirates, and now the EU – validates the transformative potential of this novel medicine,” Brian Goff, chief executive officer at Agios, said in a statement.
The approval is based on positive results from two Phase 3 trials, ENERGIZE and ENERGIZE-T, which evaluated the drug in non-transfusion-dependent and transfusion-dependent patients, respectively. In the U.S., the drug is marketed as AQVESME for thalassemia and generated 242 new prescriptions in its first quarter, showing strong early demand.
This decision opens a substantial new market for Agios, which has a $1 billion peak sales forecast for the drug. The company has partnered with Avanzanite Bioscience B.V. to commercialize and distribute PYRUKYND across Europe, where an estimated 18,000 to 23,000 people live with the rare blood disorder.
Thalassemia is an inherited disease that disrupts hemoglobin production, leading to severe anemia and other complications. The EU approval covers both alpha- and beta-thalassemia, regardless of a patient's need for regular blood transfusions.
“The Phase 3 results demonstrate the potential for PYRUKYND to address this burden and improve outcomes for those in need, regardless of their genotype or transfusion status,” said Dr. Maria Domenica Cappellini, a lead investigator in the clinical program from the University of Milan.
The ENERGIZE study in 194 non-transfusion-dependent patients met its primary endpoint of a sustained increase in hemoglobin concentration. The ENERGIZE-T study in 258 transfusion-dependent patients met its primary endpoint of achieving a 50 percent or greater reduction in the number of transfused red blood cell units.
The approval further solidifies mitapivat as a cornerstone of Agios' rare hematology strategy. The company recently submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to expand mitapivat's use to sickle cell disease, another inherited blood disorder. That filing is being advanced under an accelerated approval pathway, with a decision expected in the coming months.
The European approval signals growing momentum for mitapivat as a key commercial asset for Agios. Investors will now watch for the sales ramp-up from its European partner Avanzanite and the FDA's upcoming decision on the sickle cell disease application.
This article is for informational purposes only and does not constitute investment advice.
